Corporate Report - Evalve Inc

Login or register to view PDF.


Early clinical data in a subset of the initial non-randomized patient cohort n=54, matched data) shows that when MR is successfully reduced with the MitraClip device, heart failure symptoms improve as measured by the New York Heart Association functional class. Specifically, 75% of the patients improved by at least one class or more.

Recently published data in the New England Journal of Medicine├óÔé¼ÔÇØ from the Mayo Clinic and in Circulation├óÔé¼ÔÇØby Dr Rosenhek from Europe shows that the majority of patients with severe MR, even when initially asymptomatic, progress to heart failure, die, or need surgery.

Evalve anticipates that the MitraClip device will be available commercially in the US and Canada by the end of 2010 to provide a less invasive, potentially safer treatment alternative to surgical treatment for MR.

More information about MR and EVEREST II can be found at "